Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome (SINTRA-REV)

Clinical Trial ID NCT01243476

Rank	Title	Journal	Year	PubWeight™‹?›
1	International scoring system for evaluating prognosis in myelodysplastic syndromes.	Blood	1997	20.41
2	Efficacy of lenalidomide in myelodysplastic syndromes.	N Engl J Med	2005	8.80
3	Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.	N Engl J Med	2006	8.16
4	The evolution of thalidomide and its IMiD derivatives as anticancer agents.	Nat Rev Cancer	2004	3.58
5	The role of lenalidomide in the management of myelodysplasia with del 5q.	Br J Haematol	2008	1.41
6	The myelodysplastic syndrome(s): a perspective and review highlighting current controversies.	Leuk Res	2003	1.40
7	Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies.	Semin Oncol	2001	0.97
8	Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy.	Clin Exp Allergy	1995	0.88
9	New approaches to the treatment of myelodysplasia.	Oncologist	2002	0.88
10	Treatment of the 5q- syndrome.	Hematology Am Soc Hematol Educ Program	2006	0.75